Can a trial carried out in China back a US approval? Investors in anti-PD-(L)1 players will find out soon enough.
PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.
A handful of small caps, including Sensei and PDS, jumped on Asco abstract data, with much more news to come.
The Relativity-047 study shows that relatlimab has a big safety advantage over Yervoy, with just a slight decrease in clinical benefit.
Key catalysts approach for Orphazyme, Gemini and Immutep.
Next week’s virtual meeting could resuscitate Ox40 agonists, but an important omission will disappoint.
The French company has taken a look at its R&D portfolio, and made some radical changes in oncology and diabetes.